

Press release from Emotra AB (publ)
Kista, 22 February 2022

Emotra AB (publ) intends to list on a different exchange

On 18 February 2022, Emotra AB (“Emotra” or “the Company”) disclosed that the Company had been informed by Spotlight Stock Market (“Spotlight”) of their decision to halt their listing review of the Company. Emotra is now announcing how it plans to proceed until its shares are listed on another official exchange.

On 18 February 2022, Emotra disclosed that Spotlight’s ongoing listing review has been halted immediately. Spotlight has justified this decision by saying that Emotra has submitted incorrect information during the course of the review, without being able to satisfactorily specify which information they are referring to. The Company denies these allegations. Neither the Company nor its counsel are able to understand Spotlight’s behaviour and find it regrettable. Neither Emotra’s Board nor its management team have provided incorrect data and have always strived to promptly answer all queries in a transparent and truthful manner.

As Spotlight has decided to de-list Emotra, that is the situation the Company must address. Emotra’s Board of directors and management team are convinced that the Company’s product, NeuraMetrix TC, has the potential to fundamentally improve the health care sector’s ability to diagnose several neurological disorders at an early stage. Furthermore, the product is in an advanced development stage with buyers in waiting in the pharmaceutical industry and academic research, of which a number of American customers have already purchased the product.

For this reason, Emotra’s Board and management team will continue to work with the international market launch of NeuraMetrix TC. In parallel, the Company will with all due haste initiate the process of listing Emotra on another exchange and will continue to keep its shareholders informed of its progress. The Board’s ambition is to make this period as short as possible.

The last trading day on Spotlight will be 18 March 2022.

For further information, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail:
daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company’s methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary, and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden
Tel: +46 732-34 41 93, www.emotra.se